Interesting Images225Ac-PSMA-617 Radioligand Posttherapy Imaging in Metastatic Castrate-Resistant Prostate Cancer Patient Using 3 PhotopeaksVatsa, Rakhee PhD*,†; Sood, Ashwani DNB*,†; Vadi, Shelvin Kumar MD*,†; Das, Chandan Krushna MD, DM†; Kaur, Komalpreet MSc*,†; Parmar, Madan MSc*,†; Mittal, Bhagwant Rai MD, DNB*Author Information From the *Department of Nuclear Medicine, Nehru Hospital †Medical Oncology, Regional Cancer Center, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Received for publication August 30, 2019; revision accepted February 16, 2020. Conflicts of interest and sources of funding: none declared. Correspondence to: Bhagwant Rai Mittal, MD, DNB, Department of Nuclear Medicine, Nehru Hospital, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India. E-mail: firstname.lastname@example.org. Clinical Nuclear Medicine: June 2020 - Volume 45 - Issue 6 - p 437-438 doi: 10.1097/RLU.0000000000003031 Buy Metrics Abstract PSMA-based radioligand therapies have shown the beneficial effect in metastatic castrate-resistant prostate cancer (mCRPC) patients when they become refectory to the established treatments with associated potential toxicities and high mortality rate. 225Ac-PSMA therapy is known to be remarkably effective in substantially pretreated mCRPC patients. However, posttherapy imaging is usually not performed as alpha emitters are really difficult to image. We presents a patient of mCRPC treated with 225Ac-PSMA-617, and his posttherapy whole-body scans acquired by using 3 different photopeaks (78, 218, and 440 keV) fairly demonstrated the tracer's distribution and the efficacy of targeted alpha therapy. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.